Congenital melanocytic naevi are melanocytic naevi present at birth. This type of birthmark occurs in an estimated 1% of infants worldwide. They have a small risk of developing melanoma or neurocutaneous melanosis. However, there is no need for prophylactic removing a benign looking CMN to prevent melanoma. An adequate follow up is enough to detect melanoma. Indication for treatment are: CMN suspect for melanoma, CMN who are difficult to follow up or for cosmetic reasons. Different techniques are known as a treatment for CMN such as: laser, curettage and excision. Since CMNs have a large impact on patients life, patients and health care professionals need good research to focus their treatment strategy on.
ContributorsN. den Hertog
Prof. Dr. S.G.M.A. Pasmans
Dr. M.M. Pleumeekers
Dr. O. Lapid
Prof. dr. P.I. Spuls
Dr. A. Wolkerstorfer
Prof. Dr. J. Kottner
C.J.A. van Eijsden
Emeritus Prof. dr. C.M.A.M. van der Horst
Dr. A.C. Fledderus
Disease Category: Skin
Disease Name: Congenital melanocytic naevi
Age Range: 0 - 100
Sex: Either
Nature of Intervention: Observation, Surgery
- Clinical experts
- Consumers (caregivers)
- Consumers (patients)
- Epidemiologists
- Families
- Journal editors
- Methodologists
- Patient/ support group representatives
- Researchers
- Statisticians
- COS for clinical trials or clinical research
- COS for practice
- Recommendations for outcome measures (measurement/how)
- Consensus conference
- Consensus meeting
- Delphi process
- Focus group(s)
- Literature review
- Survey
- Systematic review
Previously, a systematic review and focus groups were conducted to identify outcomes reported in CMN research and care. In an e-Delphi study and additional consensus meeting, core outcomes were selected. Then, outcome measurement instruments used for to measure these outcomes in CMN research were identified through a systematic review. Currently, the steps within the OCOMEN project are: 1) an expert survey to identify outcome measurement instruments used in CMN care; 2) investigating measurement properties of these instruments; 3) a consensus procedure to select core outcome measurement instruments for CMN.”